A novel cytotoxic drug combination, PEEC, has been tested in the initial or salvage treatment of lymphomas. The PEEC combination alone is active in high grade or intermediate grade NHL with two complete and two partial remissions out of four patients so treated.
When combined with standard CHOP therapy using an alternating regime, seven out of 11 patients obtained a complete remission and four partial remission. Ten patients were well, off treatment, beyond one year from presentation. The combination was less impressive, however, as salvage therapy with two partial responses in a heavily pre-treated group of nine patients.
TaylorREMcElwainTJBarrettAPeckhamMJ. Etoposide as a single agent in relapsed advanced lymphomas. A Phase II Study. Cancer-Chemother-Pharmacol1982; Vol 7(2–3): 175–7 ISSN 0344–5704.
2.
HancockBW. Vindesine, Etoposide (VP-16) and Prednisolone (VEP) in relapsed patients with Grade II non-Hodgkin's lymphoma. Semin-Oncol1985 Mar; Vol 12 (1 Suppl 2): 26–8, ISSN 0093–7754.
3.
CabanillasFHagemeisterFBBodeyGPFreireichEJ. IMVP-16: An effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. Blood1982; Sep Vol 60(3): 693–7, ISSN 0006–4971.
4.
FisherRIDe VitaVTHubbardSMDiffuse aggressive lymphomas; increased survival after alternating flexible sequences of PROMACE and MOP chemotherapy. Ann Int Med1983; Vol 98: 304–309.
5.
ArmitageJODickFRCorderMP. Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP). Cancer1982; 15: 1695–1702.
6.
ArmitageJOFyfeMELewisJ. Long term remission durability and functional status of patients treated for diffuse histiocytic lymphoma with CHOP Regimen. J Clin Oncol1984; Vol 2: 898–902.
7.
SkarinATCanellosGPRosenthalDSImproved prognosis in diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). J Clin Oncol1983; Vol 1: 91–98.
8.
KlimoConnors JM. MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Int Med1985; 102: 596–602.
9.
ToddMCadmanESpiroPA follow-up of a randomised study comparing two chemotherapy treatments for advanced diffuse histiocytic lymphoma. J Clin Oncol1984; 2: 986–993.
10.
SweetDLGolombHMUltmannJECyclophosphamide, vincristine, methotrexate with folinic acid rescue and cytarabine (COMLA) combination sequential chemotherapy for advanced diffuse histiocytic lymphoma. Ann Int Med1980; 92: 785–790.
11.
CorbonePPKaplanHSMusshoffKSmithersDWTubianaM. Report on the committee of Hodgkin's Disease staging. Cancer Research1971; 31: 1860–1861.
12.
JagannathSVelasquezWSTuckerSLManningJTMcLaughtonPFullerLM. Stage IV diffuse large cell lymphoma: A long-term analysis. J Clin Oncol1985; 83: 39–47.
13.
CabanillasFCBurgessMDBodeyGPFreireichEJ. Sequential chemotherapy and late intensification for malignant lymphomas of aggressive histological type. Am J Med1983: Vol 74: 382–388.
14.
KozinerBSklaroffRLittleDNHL III protocol 6-drug combination chemotherapy for non-Hodgkin's lymphoma. Cancer1984; 153: 2592–2600.
15.
CrowtherD. New approaches to the management of patients with non-Hodgkin's lymphoma of high grade pathology. Br J Cancer1981; 43: 417–435.
16.
CabanillasFCBurkeJSSmithTLMoonTEButlerJJRodriguezV. Factors predicted for response and survival in patients with advanced non-Hodgkin's lymphoma, Arch Intern Med1978; 138: 413–418.
